Roche Holding AG
RHO6
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Stocks News & Analysis
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
The latest take from our equity research analysts.
stocks
Coca-Cola earnings: Billion-dollar brands and consumer engagement remain growth priorities
Despite macro and geopolitical challenges, Coca-Cola managed to increase sales in line with its long-term target.
stocks
Unwarranted drop in ASX share
Jittery investors misinterpret an audit for an existential crisis.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 97.30 | 1.06% |
| CAC 40 | 8,340.07 | 12.19 | 0.15% |
| DAX 40 | 24,941.73 | 46.12 | -0.18% |
| Dow JONES (US) | 50,252.28 | 64.14 | 0.13% |
| FTSE 100 | 10,445.34 | 91.50 | 0.88% |
| HKSE | 27,266.38 | 83.23 | 0.31% |
| NASDAQ | 23,107.35 | 4.88 | 0.02% |
| Nikkei 225 | 57,650.54 | 1,286.60 | 2.28% |
| NZX 50 Index | 13,507.28 | 60.91 | 0.45% |
| S&P 500 | 6,955.10 | 13.29 | 0.19% |
| S&P/ASX 200 | 9,014.80 | 98.80 | 1.11% |
| SSE Composite Index | 4,131.98 | 3.61 | 0.09% |